Clovis Oncology traded at $1.48 this Friday August 12th, increasing $0.03 or 2.07 percent since the previous trading session. Looking back, over the last four weeks, Clovis Oncology gained 39.84 percent. Over the last 12 months, its price fell by 69.04 percent. Looking ahead, we forecast Clovis Oncology to be priced at 1.61 by the end of this quarter and at 1.48 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.48
Daily Change
2.07%
Yearly
-69.04%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 142.60 0.52 0.37% 22.42%
Acadia Pharmaceuticals 16.40 0.66 4.19% -6.71%
Acorda Therapeutics 0.47 0.01 1.52% -86.93%
Agenus 2.97 0.30 11.24% -51.71%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Anika Therapeutics 22.38 0.64 2.94% -46.51%
Arrowhead Research 47.29 1.66 3.64% -21.86%
AstraZeneca 10,712.00 206.00 1.96% 27.13%
Astrazeneca 66.64 1.99 3.08% 13.95%
Clovis Oncology 1.48 0.03 2.07% -69.04%
Enanta Pharmaceuticals 67.99 1.50 2.26% 44.20%
Esperion Therapeutics 6.70 0.06 0.90% -51.83%
GlaxoSmithKline 1,450.00 50.00 3.57% -2.80%
Halozyme Therapeutics 43.14 -0.22 -0.51% 4.03%
Heron Therapeutics 5.30 0.43 8.83% -52.04%
Incyte Corp 73.99 0.23 0.31% 0.71%
Insmed 27.26 0.51 1.91% 15.70%
Ligand Pharmaceuticals 106.36 4.39 4.31% -0.43%
Eli Lilly 308.08 6.91 2.29% 16.60%
Merck & Co 91.02 2.09 2.35% 18.64%
Mirati Therapeutics 86.37 5.92 7.36% -38.38%
Neurocrine Biosciences 105.63 0.75 0.72% 18.53%
Novartis 80.10 -0.94 -1.16% -6.82%
Puma Biotechnology 3.51 -0.04 -1.13% -51.65%
Pfizer 50.11 1.82 3.77% 3.36%
Ultragenyx Pharmaceutical 51.57 0.32 0.62% -44.39%
Rigel Pharmaceuticals 1.54 0.14 10.00% -58.60%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%
Sangamo BioSciences 6.33 0.51 8.76% -37.01%
Veracyte 26.05 0.56 2.20% -35.76%
Intrexon 2.37 0.05 2.16% -61.40%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT).